id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-263267-oj7rmy8m	Taccone, Fabio S	Hydroxychloroquine in the management of critically ill patients with COVID-19: the need for an evidence base	2020-04-15		.txt	text/plain	1152	55	42	Early results from clinical studies conducted in China suggest that chloroquine use might have been associated with reduced fever, increased resolution of lung lesions on CT, and delayed disease progression. 6,7 Results of two French studies suggested that hydroxychloroquine could reduce the viral load in patients with COVID-19in particular, if combined with azithromycin 8,9 (table) . 12 In a second Chinese trial in 62 patients, Zhaowei Chen and colleagues showed that hydroxychloroquine treatment was associated with a shorter time to clinical recovery (temperature and cough) than placebo; 13 the participants had mild disease (SaO 2 /SpO 2 >93% or PaO 2 /FiO 2 >300) and it is not possible to extrapolate these results to critically ill patients. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: an observational study	./cache/cord-263267-oj7rmy8m.txt	./txt/cord-263267-oj7rmy8m.txt